Does taurine actually slow aging?

Taurine is an amino sulfonic acid. Your body makes it, you get more from meat and seafood, it sits in high concentrations in muscle, heart, retina and brain, and it has been in energy drinks for decades. It is cheap, it is well tolerated, and until 2023 nobody thought of it as an anti-aging compound.

Then a large international collaboration published a paper in Science, and the category was invented overnight.

What the 2023 paper actually said

The claim had two halves, and keeping them apart is the entire job of this report.

Half one, the observation: circulating taurine declines with age in mice, monkeys and humans.

Half two, the intervention: reversing that decline through supplementation increased health span and life span in mice, and health span in monkeys. The paper also reported mechanistic effects, reduced cellular senescence, less mitochondrial dysfunction, less DNA damage, and lower inflammation, plus a human correlation between lower taurine and several age-related diseases.

Note what the authors concluded from their own work. Not that taurine slows human aging. Their closing sentence says clinical trials in humans "seem warranted" to test whether taurine deficiency might drive aging in people. That is a proposal, phrased as a proposal. The paper was appropriately hedged. The supplement industry was not.

And notice the logical structure, because it is load-bearing. The framing is deficiency. The story is that you are losing something and should replace it. That story only works if you are actually losing it.

Two independent groups went to check the premise

In June 2025, Science published a study led by researchers at the National Institute on Aging asking a deliberately narrow question: is taurine an aging biomarker?

They looked at three geographically distinct human cohorts, plus nonhuman primates and mice. Critically, they measured both ways: longitudinally, following the same individuals over time, and cross-sectionally, sampling different people at different ages. That distinction matters more than almost anything else here, and I will come back to it.

Their finding was that circulating taurine increased or remained unchanged with age, in the humans, in the monkeys and in the mice. They also report considerable variability in how taurine related to age-related outcomes in motor function and energy homeostasis. Their conclusion is that changes in circulating taurine are "not a universal feature of aging."

Two months later, in August 2025, a group in Montreal published in Aging Cell, testing the same premise in a different population: 137 men aged 20 to 93, both physically inactive and physically active. They found no association between circulating taurine and age, and none with muscle mass, strength, physical performance or mitochondrial function. Their framing is direct, describing the result as challenging the implication of taurine deficiency as a primary driver of aging in humans.

Two independent groups, different designs, different countries, different cohorts, same direction of answer.

The methodological point worth stealing

Why would one group see a decline and others not?

The most likely answer is the one hiding in the NIA study's design, and it generalizes far beyond taurine. If you sample 30-year-olds and 80-year-olds today and compare their blood, you are not watching people age. You are comparing two different groups of people who were born fifty years apart, ate differently, exercised differently, and, relevant here, survived. That is a cross-sectional design, and it confounds aging with cohort effects and with survivorship.

Following the same individuals over years is a different and much more expensive question, and it is the one that answers "does this fall as a person ages." The NIA group did both, and reported that neither showed the decline.

This is the same failure mode I keep running into on this beat: a measurement that looks like it is about time is often about the people you happened to measure. When you see "X declines with age" attached to a supplement, the first question is whether anyone followed the same person twice.

What the human trials do show, which is not nothing

Here is where the story gets more interesting than "debunked," and where most coverage stops too early.

Taurine has been through a lot of randomized controlled trials. A 2024 systematic review and meta-analysis in Nutrition & Diabetes pooled 25 RCTs covering 1,024 participants, at doses from 0.5 to 6 grams per day, with follow-up periods ranging from 5 to 365 days. Against controls, taurine produced statistically significant reductions in:

Systolic blood pressure: −4.0 mmHg (95% CI −7.29 to −0.71, p = 0.017).
Diastolic blood pressure: −1.5 mmHg (95% CI −2.48 to −0.54, p = 0.002).
Fasting blood glucose: −5.9 mg/dL (95% CI −10.75 to −1.02, p = 0.018).
Triglycerides: −18.3 mg/dL (95% CI −25.63 to −11.00, p < 0.001).

HDL cholesterol did not move significantly. Meta-regression found dose-dependence for diastolic blood pressure and fasting glucose. No significant adverse effects appeared versus control.

Those are real, replicated, modest cardiometabolic effects, and I want to be fair to them. A 4 mmHg systolic reduction is not trivial at population scale.

But look at what that evidence is and is not. The outcome measures are blood pressure, glucose and triglycerides. The follow-up tops out at one year and starts at five days. The populations skew toward people who already have something wrong, metabolic syndrome and cardiovascular conditions, because that is who gets enrolled in trials with those endpoints.

None of that is a longevity finding. A drug that lowers your triglycerides over twelve weeks has told you it lowers triglycerides over twelve weeks. The gap between that and "slows aging" is not a small extrapolation, it is a different claim requiring a different study.

So has anyone run the trial the 2023 paper asked for?

I went and looked at the registry rather than guessing, which is a habit I would recommend to anyone evaluating a supplement claim, because it is free and it takes four minutes.

Searching ClinicalTrials.gov for taurine against aging and longevity returns six studies, total. Several are observational, small, or about something adjacent like periodontitis or sarcopenic obesity.

The one that most directly targets the 2023 hypothesis is a randomized controlled trial at the Technical University of Munich: 4 grams of taurine daily against placebo for six months, in women and men aged 55 to 75, with outcomes including biological age by DNA methylation, metabolic biomarkers and physical fitness. Enrollment: 90 participants. It started in September 2024 and its primary completion date was 13 November 2025.

So the answer, three years after a paper in Science called for clinical trials, is that the flagship human anti-aging taurine trial enrolled ninety people for six months, and its results were not published as of this writing. That is not a criticism of the researchers, who are doing exactly the right thing at a realistic scale. It is a comment on the distance between how fast a supplement category forms and how fast the evidence for it does.

It is also worth flagging that "biological age" measured by a methylation clock is itself a surrogate endpoint, not an outcome anyone experiences. That is the same substitution I wrote about in the NMN report, where blood NAD levels stood in for the thing people actually wanted. A clock moving is evidence about a clock.

What I am not claiming

I want to be precise here, because it would be easy to overshoot in the other direction and that would be its own error.

The 2025 papers do not refute the mouse data. They address the premise that taurine declines with age in humans. Whether taurine supplementation extends life in mice is a separate question that those studies did not test and did not claim to. The mouse and monkey findings from 2023 stand as reported.

Neither 2025 study tested supplementation. Both are observational measurements of taurine levels. It remains logically possible for taurine to help someone without their taurine having declined. What collapses is the specific "deficiency" story used to sell it, which is the story on the label.

The Montreal study has real limits. It is 137 men, cross-sectional, single site, no women. It is corroborating evidence alongside the NIA work, not independent proof on its own.

Taurine is not being called dangerous here. The meta-analysis found no significant adverse effects against control across 25 trials. This report is about whether a claim is supported, not about safety.

And the honest uncertainty: the disagreement between the 2023 and 2025 measurements has not been formally resolved in the literature. Different assays, different cohorts and different sampling designs can all produce this, and until someone reconciles them directly, the correct posture is that the human decline is unsupported rather than definitively disproven.

The signal

Three things to carry out of this.

First, when a supplement is sold on a deficiency story, check the deficiency, not the benefit. The whole persuasive structure of "restore your declining X" rests on a factual claim about decline that is usually easier to verify than any efficacy claim, and is checked far less often. Here it was checked, twice, and it did not hold.

Second, a compound can have real, measured, replicated effects and still not do the thing it is being sold for. Taurine genuinely moves blood pressure and triglycerides in trials. It is marketed for longevity. Those are not the same shelf, and the trial evidence for the first is being used as ambient credibility for the second.

Third, the timeline is the tell. The gap between a single high-profile paper and a fully formed supplement category was about a week. The gap between that paper and the first dedicated human trial reading out is more than three years, and counting. Nothing about the science changed in that first week. Only the marketing did.

Not medical advice. This is educational analysis, not a recommendation — a study is not a prescription. Talk to a qualified clinician before acting on anything you read here. Full disclaimer →

Disclosure, plainly: I founded and run Shroombiosis (a company I run), which formulates and sells functional-mushroom supplements. That is a direct commercial stake in the industry this report is about, and the deficiency-story problem described here is one my own category is perfectly capable of committing: "restore what age is taking from you" is a template, and it works on mushroom marketing as well as it works on taurine. Apply this report's first rule to anything I ever publish about my own products, including checking whether the decline I am implying has actually been measured. Nothing here is sponsored and no link earns a commission; here's the full policy. A recommendation with no stake at all: for performance nutrition, Die Tryin Co. is a fellow combat-veteran-owned brand I'm glad to point people to. I don't own it and earn nothing from the link.